Muga R, Tor J, Melus R, Ginesta C, Rey-Joly C, Foz M; International Conference on AIDS.

Int Conf AIDS. 1989 Jun 4-9; 5: 131 (abstract no. W.A.P.71).

Service of Internal Medicine. Hospital de Badalona "Germans Trias i Pujol", Universitat Autonoma de Barcelona, Barcelona, Spain

OBJECTIVE: To determine seroconversion rates, clinical progression and AIDS incidence in a longitudinal study of HIV infection among intravenous drug users (IVDUs). METHODS: From June 83 to June 88, 442 non-AIDS IVDUs were enrolled in a prospective study that included: HIV antibodies (Ab) tests (EIA) and physical exams at baseline evaluation, and followed-up every 6 months. RESULTS: 133/442 (30%) of IVDUs enrolled were seronegatives (SN) and 309/442 (70%) were seropositives (SP); 178/442 (40.2%) patients were followed for a mean of 18 months and rest were controlled just one. Among SN, 38 out of 133 (28.5%) were followed-up; 10 out of 38 (26.3%) had seroconverted after keeping seronegatives for a mean of 15.8 months. 28 out of 38 cases still SN after a mean of 18 months (p=NS). Clinical status: At entry, 87/309 (28.1%) patients were asymptomatic (Group II); 151/309 (48.8%) had PGL (Group III) and 71/309 (22.9%) had ARC (Group IV). 145 out of 309 HIV infected (non-AIDS) had been followed-up for a mean of 17 months; 37/136 (27.2%) showed clinical progression of the disease. CONCLUSION: Data suggest a high prevalence of HIV infection, substantial rates of seroconversion and clinical progression. The small number of cases who developed full-blown AIDS could be due, among others, to the fact that this infection is of later appearance in our area.

Publication Types:

• Meeting Abstracts

Keywords:

• AIDS-Related Complex
• Acquired Immunodeficiency Syndrome
• Disease Progression
• HIV Antibodies
• HIV Infections
• HIV Seropositivity
• Humans
• Incidence
• Longitudinal Studies
• Prospective Studies
• Substance Abuse, Intravenous
• epidemiology

Other ID:

• 00046689

UI: 102176358

From Meeting Abstracts